Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Fda Inspections
  6. /
  7. Chartwell Pharmaceuticals LLC
FDA Inspection
•Chartwell Pharmaceuticals LLC•November 18, 2025

Chartwell Pharmaceuticals LLC – FDA Inspection, Nov 18, 2025

Record Details

This FDA Inspection record concerns Chartwell Pharmaceuticals LLC, with an inspection on November 18, 2025, issued by the New York District Office, covering human drugs.

Company
Chartwell Pharmaceuticals LLC
Inspection Date
November 18, 2025
Product Type
Human Drugs
Office
New York District Office
People
  • Lata C. Mathew
  • Mindy M. Chou (FDA Associated Person)
  • Syeda N. Mahazabin (FDA Associated Person)
View Company Profile

ID · 11d3e553-14c5-43ff-beb2-f6ce814ef92c

Inspection Facts

Official Action Indicated (OAI)

Significant objectionable conditions were found and regulatory or administrative action is recommended.

Inspection number
1277530
FDA center
Human Drugs
Project area
Drug Quality Assurance
Outcome
Form 483 issued

FDA Citations

15
  1. 21 CFR 211.100(a)Changes to Procedures Not Reviewed, Approved
  2. 21 CFR 211.101(b)Identification of new containers
  3. 21 CFR 211.160(a)Following/documenting laboratory controls
  4. 21 CFR 211.160(b)(2)In-process sample representation/identification
  5. 21 CFR 211.166(a)Written program not followed
  6. 21 CFR 211.180(e)(1)Review of representative number of batches
  7. 21 CFR 211.188Prepared for each batch, include complete information
  8. 21 CFR 211.192Investigations of discrepancies, failures
  9. 21 CFR 211.204Returned drug procedures in writing and followed
  10. 21 CFR 211.22(d)Procedures not in writing, fully followed

Showing 10 of 15 citations.

Full citation text and observation details available on the Dashboard.

Other FDA inspections of Chartwell Pharmaceuticals LLC

8
DateClassificationOfficeProject area
December 19, 2024Not classifiedNew York District OfficeDrug Quality Assurance
May 31, 2024OAINew York District OfficeGeneric Drug Evaluation
April 8, 2024VAICenter for Drug Evaluation and ResearchBioresearch Monitoring
May 24, 2023VAICenter for Drug Evaluation and ResearchDrug Quality Assurance
September 26, 2018VAICenter for Drug Evaluation and ResearchDrug Quality Assurance
View all 8 other inspections on the company page
Other documents for Chartwell Pharmaceuticals LLC
  • FDA Inspection 1257321 - 2024-12-19
  • FDA Inspection 1236033 - 2024-05-31
  • FDA Inspection 1230475 - 2024-04-08
  • FDA Inspection 1206056 - 2023-05-24
  • FDA Inspection 1068395 - 2018-09-26

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Chartwell Pharmaceuticals LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.